Navigation Links
MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results
Date:11/14/2007

d, (8) receive required regulatory approvals, (9) successfully conduct clinical trials in a timely manner, (10) establish its competitive position for its products, (11) develop and commercialize products that are superior to existing or newly developed competitor products, (12) develop products without any defects, (13) have sufficient capital resources to fund its operations, (14) protect its intellectual property rights and patents, (15) implement its sales and marketing strategy, (16) successfully attract and retain collaborative partners, (17) successfully commercialize and gain market acceptance for its Keflex products, (18) successfully obtain sufficient manufactured quantities of its drug products at acceptable rates, and (19) retain its senior management and other personnel. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. MiddleBrook undertakes no obligation to update or revise the information in this announcement, whether as a result of new information, future events or circumstances or otherwise.

MIDDLEBROOK PHARMACEUTICALS, INC.

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

Three Months Ended Sept 30, Nine Months Ended Sept 30,

2007 2006 2007 2006

Product sales $3,144,532 $2,369,975 $7,598,127 $3,566,563

Costs and

expenses:

Cost of product

sales 1,183,772 440,159 1,864,643 517,765

Research and

development 5,509,093 5,737,047 18,485,164 19,700,263

Selling, general

and administrative 6,475,742 6,069,529 20,473,947 13,001,312

Total

expenses 13,168,607 12,246,735 40,823,754 33,219,340

Loss from

opera
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... (PRWEB) July 23, 2014 On July 21, ... childhood safety advocate Jack Tracey for an episode that spoke ... the episode, Deierlein asks Tracey to talk some about the ... international in its mission, it was started right here in ... initially it was to help survivors of sexual abuse. Their ...
(Date:7/23/2014)... 23, 2014 Beverly Hills plastic ... surgery procedures to patients who want to rejuvenate their ... affecting any part of the face, Dr. Diamond empowers ... want. Throughout life, facial skin and structure develop wrinkles, ... than they really are. Each patient is different in ...
(Date:7/23/2014)... July 23, 2014 Seedstock today announced ... and Agriculture (2003-2010) Arthur Gen “A.G.” Kawamura, will deliver ... Agriculture Innovation Conference – “Reintegrating Ag: Local Food Systems ... , to be held Tuesday and Wednesday, Nov. 11-12, ... benefits that result from the development of robust local ...
(Date:7/23/2014)... July 23, 2014 Follow ... vital role in the marketing mix, with its ... to influencing customers’ purchase decision. In a competitive ... and efficient packaging provides ample opportunities for sales ... advanced packaging technologies such as blister and other ...
(Date:7/23/2014)... 2014 FCCI Insurance Group has been ... American Heart Association for helping employees eat better and ... Fit-Friendly Worksite in 2013, 2011, and 2010, and as ... employee health and wellness an important priority. We’re committed ... at the top of their game, and we are ...
Breaking Medicine News(10 mins):Health News:My Positive Perspective Airs Episode to Raise Attention to the Group Darkness to Light 2Health News:Beverly Hills Plastic Surgeon, Dr. Diamond, is Now Offering Facial Plastic Surgery Procedures 2Health News:Seedstock Names Former CA Secretary of Agriculture as Sustainable Agriculture Conference Keynote Speaker 2Health News:Seedstock Names Former CA Secretary of Agriculture as Sustainable Agriculture Conference Keynote Speaker 3Health News:Increasing Focus on Packaging as a Marketing Tool Drives the Blister & Other High Visibility Packaging Market, According to New Report by Global Industry Analysts, Inc. 2Health News:Increasing Focus on Packaging as a Marketing Tool Drives the Blister & Other High Visibility Packaging Market, According to New Report by Global Industry Analysts, Inc. 3Health News:Increasing Focus on Packaging as a Marketing Tool Drives the Blister & Other High Visibility Packaging Market, According to New Report by Global Industry Analysts, Inc. 4Health News:FCCI Insurance Group Recognized as an American Heart Association Fit-Friendly Worksite 2Health News:FCCI Insurance Group Recognized as an American Heart Association Fit-Friendly Worksite 3
... ... of the best medical malpractice attorneys in New York, and a former ... to talk to their doctor about the benefits and risks of radiation ... how to evaluate the treatment they are getting, ,how to discuss the ...
... more likely to die in the month following their operations ... by Johns Hopkins researchers suggests. The study, to be ... Care , finds that newly diagnosed cancer patients particularly ... Type 2 diabetes have a 50 percent greater risk of ...
... new study from University of Utah psychologists found a small ... 97.5 percent of those studied, they can safely drive while ... described by the researchers as "supertaskers" constitute only 2.5 ... ability to successfully do two things at once: in this ...
... ... true alternative to smoking. They deliver more of the flavor and you don,t lose any ... MiniVap, Magic Flight, Vapir, BM Innovators, and Eterra will indroduce new models in 2010. ... (PRWEB) March 28, 2010 ...
... Affordable prices for ... ... bearing not only the responsibility of preserving the peace and saving lives but paying exorbitant ... light bars at an affordable price. With a fully interactive website and telephone ...
... ... there a link between alcohol and depression? , ... (PRWEB) March 28, 2010 -- Statistics prove the link between alcohol ... have tended to view alcohol and depression as separate issues. However increasingly, research is showing ...
Cached Medicine News:Health News:New York Medical Malpractice Attorney Recommends Cancer Patients Take Precautionary Steps Before Undergoing Radiation Therapy 2Health News:New York Medical Malpractice Attorney Recommends Cancer Patients Take Precautionary Steps Before Undergoing Radiation Therapy 3Health News:Diabetes raises risk of death in cancer surgery patients 2Health News:Few drive well while yakking on cell phones 2Health News:Few drive well while yakking on cell phones 3Health News:New Vaporizer Technologies Revolutionize Smoking 2Health News:New Vaporizer Technologies Revolutionize Smoking 3Health News:High Quality Strobe Lights and Light Bars at an Affordable Price 2Health News:Linwood Group Reveal Whether There is a Link Between Alcohol and Depression 2Health News:Linwood Group Reveal Whether There is a Link Between Alcohol and Depression 3
(Date:7/23/2014)... 2014  Nonin Medical, Inc., the inventor of finger ... announced today that Mark VanderWerf , Nonin,s Vice ... of the American Telemedicine Association,s (ATA) Industry Council and ... The ATA is the leading international resource and advocate ... ATA and its diverse membership work to transform healthcare ...
(Date:7/23/2014)... PLYMOUTH MEETING, Pa. , July 23, ... MKT: INO) today announced successful results from ... of VGX-3100 in women with biopsy-proven cervical ... papillomavirus (HPV) types 16 or 18. Treatment ... histopathological regression of CIN2/3 to CIN1 or ...
(Date:7/23/2014)... July 23, 2014  Lightlake Therapeutics Inc. ("Lightlake") ... based on its expertise in opioid antagonists, announced ... drug application ("IND") with respect to its naloxone-based ... today that it has received an additional commitment ... part of the National Institutes of Health ("NIH"), ...
Breaking Medicine Technology:Nonin Medical Announces that Mark VanderWerf has been Elected Chairman of the American Telemedicine Association's Industry Council 2Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 2Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 3Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 4Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 5Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 3
... Diagnostics Incorporated (NYSE: DGX ), the world,s ... that for the third quarter ended September 30, 2010, ... $1.13 per diluted share, from $192 million, or $1.02 ... Third quarter 2010 results include a benefit of $0.08 ...
... Stryker Corporation (NYSE: SYK ) reported operating ... Third Quarter Highlights ... as reported) to $1,768 million Orthopaedic Implants sales increased ... MedSurg Equipment sales increased 16.3% on a constant currency ...
Cached Medicine Technology:Quest Diagnostics Reports Third Quarter 2010 Financial Results; Updates Guidance for 2010 2Quest Diagnostics Reports Third Quarter 2010 Financial Results; Updates Guidance for 2010 3Quest Diagnostics Reports Third Quarter 2010 Financial Results; Updates Guidance for 2010 4Quest Diagnostics Reports Third Quarter 2010 Financial Results; Updates Guidance for 2010 5Quest Diagnostics Reports Third Quarter 2010 Financial Results; Updates Guidance for 2010 6Quest Diagnostics Reports Third Quarter 2010 Financial Results; Updates Guidance for 2010 7Quest Diagnostics Reports Third Quarter 2010 Financial Results; Updates Guidance for 2010 8Quest Diagnostics Reports Third Quarter 2010 Financial Results; Updates Guidance for 2010 9Quest Diagnostics Reports Third Quarter 2010 Financial Results; Updates Guidance for 2010 10Quest Diagnostics Reports Third Quarter 2010 Financial Results; Updates Guidance for 2010 11Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 2Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 3Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 4Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 5Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 6Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 7Stryker Reports 7% Sales Growth, 14% Adjusted Net Earnings Growth for Quarter Ended September 30, 2010 8
... Forma 1400 Series ... specifically to revolutionize working ... cabinet. The most comfortable, ... Class II cabinet on ...
... The Premier 12 Holter Analysis Kit incorporates ... Dispersion with other powerful DMS Holter analysis ... TWA analysis possible in less than 10 ... TWA, for visual verification and validation. The ...
... Designed for ease of use and patient ... smooth edges for comfort and is available ... to a perfect fit. For hard to ... trach collar to your specifications. Don't just ...
... more comfortable, and you will too., ... and to avoid the knotty problems associated ... ties, consider the Dale® Tracheostomy Tube Holder. ... narrow fastener tabs of the Dale® Tracheostomy ...
Medicine Products: